You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine
|
|---|---|
| Published in |
Cancer Discovery, September 2018
|
| DOI | 10.1158/2159-8290.cd-18-0275 |
| Pubmed ID | |
| Authors |
Andrew J Aguirre, Jonathan A Nowak, Nicholas D Camarda, Richard A Moffitt, Arezou A Ghazani, Mehlika Hazar-Rethinam, Srivatsan Raghavan, Jaegil Kim, Lauren K Brais, Dorisanne Ragon, Marisa W Welch, Emma Reilly, Devin McCabe, Lori Marini, Kristin Anderka, Karla Helvie, Nelly Oliver, Ana Babic, Annacarolina Da Silva, Brandon Nadres, Emily E Van Seventer, Heather A Shahzade, Joseph P St Pierre, Kelly P Burke, Thomas Clancy, James M Cleary, Leona A Doyle, Kunal Jajoo, Nadine J McCleary, Jeffrey A Meyerhardt, Janet E Murphy, Kimmie Ng, Anuj K Patel, Kimberly Perez, Michael H Rosenthal, Douglas A Rubinson, Marvin Ryou, Geoffrey I Shapiro, Ewa Sicinska, Stuart G Silverman, Rebecca J Nagy, Richard B Lanman, Deborah Knoerzer, Dean J Welsch, Matthew B Yurgelun, Charles S Fuchs, Levi A Garraway, Gad Getz, Jason L Hornick, Bruce E Johnson, Matthew H Kulke, Robert J Mayer, Jeffrey W Miller, Paul B Shyn, David A Tuveson, Nikhil Wagle, Jen Jen Yeh, William C Hahn, Ryan B Corcoran, Scott L Carter, Brian M Wolpin |
| Abstract |
Clinically relevant subtypes exist for pancreatic ductal adenocarcinoma (PDAC), but molecular characterization is not yet standard in clinical care. We implemented a biopsy protocol to perform time-sensitive whole exome sequencing and RNA-sequencing for patients with advanced PDAC. Therapeutically relevant genomic alterations were identified in 48% (34/71) and pathogenic/likely pathogenic germline alterations in 18% (13/71) of patients. Overall, 30% (21/71) of enrolled patients experienced a change in clinical management as a result of genomic data. Twenty-six patients had germline and/or somatic alterations in DNA-damage repair genes, and 5 additional patients had mutational signatures of homologous recombination deficiency but no identified causal genomic alteration. Two patients had oncogenic in-frame BRAF deletions, and we report the first clinical evidence that this alteration confers sensitivity to MAP-kinase pathway inhibition. Moreover, we identified tumor/stroma gene expression signatures with clinical relevance. Collectively, these data demonstrate the feasibility and value of real-time genomic characterization of advanced PDAC. |
X Demographics
The data shown below were collected from the profiles of 101 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 38 | 38% |
| France | 3 | 3% |
| Australia | 3 | 3% |
| India | 3 | 3% |
| Spain | 3 | 3% |
| United Kingdom | 3 | 3% |
| Argentina | 2 | 2% |
| Mexico | 2 | 2% |
| Turkey | 2 | 2% |
| Other | 9 | 9% |
| Unknown | 33 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 54 | 53% |
| Scientists | 30 | 30% |
| Practitioners (doctors, other healthcare professionals) | 14 | 14% |
| Science communicators (journalists, bloggers, editors) | 2 | 2% |
| Unknown | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 268 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 268 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 51 | 19% |
| Student > Ph. D. Student | 47 | 18% |
| Other | 21 | 8% |
| Student > Bachelor | 18 | 7% |
| Student > Master | 15 | 6% |
| Other | 37 | 14% |
| Unknown | 79 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 63 | 24% |
| Medicine and Dentistry | 60 | 22% |
| Agricultural and Biological Sciences | 26 | 10% |
| Immunology and Microbiology | 6 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 1% |
| Other | 19 | 7% |
| Unknown | 90 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 107. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 November 2023.
All research outputs
#401,089
of 25,774,185 outputs
Outputs from Cancer Discovery
#201
of 4,156 outputs
Outputs of similar age
#8,380
of 346,331 outputs
Outputs of similar age from Cancer Discovery
#8
of 96 outputs
Altmetric has tracked 25,774,185 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,156 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.2. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 346,331 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 96 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.